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Markers of Oxidative Stress in Dogs with Myxomatous Mitral Valve
Disease are Influenced by Sex, Neuter Status, and Serum Cholesterol
Concentration
M.J. Reimann, J. H€aggstr€om, J.E. Møller, J. Lykkesfeldt, T. Falk, and L.H. Olsen
Background: Cardiovascular disease has been associated with oxidative stress, which has been suggested to contribute to
myocardial remodeling in human patients. Little is known about the relationship between myxomatous mitral valve disease
(MMVD) and oxidative stress in dogs.
Objective: To determine whether clinical stage of MMVD is associated with changes in the plasma concentrations of cer-
tain markers of oxidative stress in clinically healthy dogs and dogs with MMVD.
Animals: Seventy ﬁve privately owned dogs: 59 cavalier King Charles Spaniels (CKCS) with diﬀerent severities of MMVD
and 16 dogs of diﬀerent breeds with clinical signs of congestive heart failure (CHF) caused by MMVD.
Methods: Markers of oxidative stress including malondialdehyde (MDA), oxidized low-density lipoprotein (oxLDL), and
vitamin E (a-tocopherol and c-tocopherol) were measured in plasma and their association with clinical stage of MMVD was
assessed by regression analyses.
Results: Plasma oxLDL concentration was signiﬁcantly lower in female dogs compared with males (P = .01). Signiﬁcantly
higher plasma c-tocopherol concentrations were found in neutered (P = .003) dogs. Vitamin E (a-tocopherol [P = .0004] and
c-tocopherol [P = .003]) was associated with body condition score (BCS), but the association disappeared when cholesterol
was included in the analyses. All markers of oxidative stress (MDA, oxLDL, and vitamin E) were positively associated with
serum cholesterol concentration (P ≤ .04), but none were associated with clinical stage of MMVD.
Conclusions: In conclusion, markers of oxidative stress are associated with sex, BCS, neuter status, and cholesterol. The
results cannot conﬁrm a relationship between oxidative stress and clinical stage of the disease in dogs with MMVD.
Key words: Malondialdehyde; Oxidized low-density lipoprotein; Valvular disease; Vitamin E.
Oxidative stress describes an imbalance betweenproduction of reactive oxygen species (ROS) and
antioxidant defenses in the body.1 The ROS may cause
tissue damage by oxidative modiﬁcation of lipids,
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ROS reactive oxygen species
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proteins, and DNA and, in addition, by the release of
pro-inﬂammatory cytokines.2,3 Because it is diﬃcult to
measure ROS directly, indirect measures of circulating
concentrations of oxidative products such as malondi-
aldehyde (MDA) and oxidized low-density lipoproteins
(oxLDL) are used to estimate the degree of oxidative
stress.3,4 Other indirect markers of oxidative stress
include measurement of circulating concentrations of
antioxidants such as vitamin E.3
The pathogenesis of myxomatous mitral valve dis-
ease (MMVD) remains unresolved.5 It is characterized
by progressive myxomatous degeneration of the mitral
valves resulting in insuﬃcient coaptation of the valve
leaﬂets and mitral regurgitation (MR).6–8 Chronic MR
causes left ventricular (LV) and atrial volume overload
with subsequent risk of remodeling and myocardial
alterations.9–13 Oxidative stress has been suggested to
contribute to development of remodeling and dysfunc-
tion in human patients with MR.14,15 In agreement,
in vitro studies have demonstrated that overstretching
and cyclic stretch of cardiomyocytes increase ROS pro-
duction, and the process may be involved in mediating
apoptosis and contractile dysfunction.16,17 Interestingly,
in a study of experimentally induced heart failure in
guinea pigs, increased oxidative stress was reported in
the transition phase from myocardial hypertrophy to
heart failure.18 Few previous studies have suggested
altered oxidative status in dogs with either naturally
occurring or experimentally induced MMVD.19–21
The aim of our study was to investigate whether or
not clinical stage of MMVD is associated with
changes in plasma concentrations of biomarkers of
oxidative stress in healthy dogs and dogs with
MMVD.
Materials and Methods
Our study included client-owned dogs ≥4 years of age with no
MMVD or diﬀerent clinical stages of MMVD. All owners agreed
to participate by written informed consent and the study was
approved by the Danish Animal Experiments Inspectorate
(license no. 2012-15-2934-00700). Exclusion criteria included med-
ical treatment (except for cardiac treatment) and presence of car-
diac disorders other than MMVD and noncardiac illnesses. All
dogs were recruited at the University of Copenhagen, Faculty of
Health and Medical Sciences, and Din Veterin€ar Animal Hospi-
tal, Helsingborg, Sweden, between October 2011 and February
2012 and examined by a standardized protocol in the following
order: interview with the owner, collection of venous blood,
physical examination, blood pressure measurement, and echocar-
diography. Owner interview included passive exposure to smoke,
deﬁned as dogs living in a home where the owner smoked
indoors. Body condition score (BCS) was graded 1–9.22 Left api-
cal systolic heart murmur intensity was graded 1–6.23 Blood pres-
sure was determined by use of high deﬁnition oscillometry
equipmenta,24 on the proximal part of the tail and an average of
5 repetitive measurements was used as previously described.25 To
verify the diagnosis of CHF and to rule out concomitant pul-
monary disease, dogs showing signs of overt CHF had thoracic
radiographs (laterolateral and dorsoventral) taken (except 4 dogs
because of logistic reasons). All dogs were part of previous
studies concerning echocardiography and biomarkers in
MMVD.21,26,27
Blood Sampling
Blood was collected from the jugular vein with a vacutainer system
connected to a 21-G butterﬂy catheter. Dogs were fasted 6–18 hours
before blood sampling. To assess health status, CBC and serum bio-
chemistry analysis was performed on all dogs. Plasma was separated
by centrifugation within 30 minutes of collection and stored in
cryotubes at 80°C until batched analysis was performed. Plasma
vitamin E (a-tocopherol and c-tocopherol) was analyzed in duplicate
by high-performance liquid chromatography (HPLC) with electro-
chemical detection as previously described.28 PlasmaMDA was deter-
mined in triplicate as its genuine MDA-thiobarbituric acid adduct by
HPLC with ﬂuorescence detection as described previously.29 Plasma
oxLDL was assayed in triplicate with a commercially available
ELISA kitb according to the manufacturer’s instructions, with mouse
monoclonal antibodies (mAb 4E6) against a conformational epitope
at the oxidized apolipoprotein B100 of the oxLDL.30
One dog with an inexplicably high concentration of plasma MDA
(3.99 lmol/L) and 1 dog with an inexplicably high concentration of
plasma oxLDL (35.4 U/L) were excluded from statistical analysis of
MDA and oxLDL, respectively, because they were considered to be
outliers based on visual inspection of the residual plots.
Plasma cardiac troponin-I (cTnI) concentration was analyzed in
duplicate with an ELISA kitc as described elsewhere.31
Echocardiography
Echocardiographic examination was performed and evaluated
by a single operator (LHO). During the oﬄine echocardiographic
analysisd , the operator was blinded to the identity and clinical sta-
tus of the dog. A standardized transthoracic echocardiographic
examination from parasternal and apical windows32 was per-
formed and digitally stored on an ultrasonographic unite with 3S
and 5S ultrasound transducers and continuous electrocardio-
graphic (ECG) monitoring.
Severity of MR was assessed from the left apical 4-chamber
view by 2D color Doppler ﬂow mapping and was classiﬁed as min-
imal (<20%), mild (20–50%), or moderate-severe (>50%) based on
regurgitant jet area relative to left atrial area.33,34 Left atrial-to-
aortic root ratio (LA/Ao) at the level of the aortic root was deter-
mined from the 2D right parasternal short-axis view.35 The LV
dimensions and fractional shortening (FS) were obtained from
M-mode short-axis images.36 All LV dimensions were normalized
to body weight (BW).37
Classification of MMVD
Clinical stage of MMVD was determined according to Ameri-
can College of Veterinary Internal Medicine (ACVIM) consensus
statement guidelines as follows: group A (Cavalier King Charles
Spaniels [CKCS] with no auscultatory heart murmur and normal
echocardiogram [MR < 20%]), group B1 (CKCS with auscultatory
heart murmur or MR ≥ 20% and LA/Ao ≤ 1.5), group B2 (CKCS
with auscultatory heart murmur or MR ≥ 20% and LA/Ao > 1.5),
and group C (dogs of various breeds with CHF).35,38 The inclusion
of dog breeds other than CKCS in group C was carried out to
increase the number of dogs. Classiﬁcation of CHF included dogs
with previous or current clinical signs of CHF (eg, cough, dysp-
nea, tachypnea, nocturnal restlessness, exercise intolerance),
echocardiographic and radiographic changes compatible with
CHF caused by MMVD, and response to treatment with diuretics.
Statistical Analysis
Data were analyzed by statistical softwaref and the level of sig-
niﬁcance was set at P < .05.
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Group associations were investigated by a nonparametric Krus-
kal-Wallis test because many groups did not follow a normal dis-
tribution. Exploratory diﬀerences among groups were assessed by
the Wilcoxon rank sum test with Bonferroni adjustment (except
for LA/Ao because this variable was used to allocate dogs into
disease groups). Fisher’s exact test was performed on categorical
data to investigate group diﬀerences (except for MR severity
because this variable was used to allocate dogs into disease
groups).
Intra-assay coeﬃcients of variation (CV) were calculated for all
markers of oxidative stress.
Univariable regression analyses were performed to evaluate
associations among the markers of oxidative stress, dog character-
istics (age, sex, BCS, passive smoking, neuter status), disease
group, cTnI, and serum cholesterol concentration. Logarithmic
transformation was performed when necessary to ensure normal
distribution of data. For the purpose of statistical analysis, BCS
group 3 and 4 and groups 6 and 7 were merged as only 1 dog was
found with a BCS 3 and 4 dogs with a BCS 7.
Multivariable regression analysis models initially were per-
formed including all explanatory variables with P < .2 in the uni-
variable regression analysis; subsequently, analyses were repeated
excluding serum cholesterol concentration as an explanatory vari-
able. Response variable residuals were tested for homogeneity of
variation based on visual inspection of residual and QQ plots and
the Shapiro-Wilks test. All response variables (oxidative stress
markers) were logarithmically transformed based on Box-Cox
analysis. Multivariable regression analyses were performed in a
backward stepwise manner based on P values. Diﬀerences among
groups in class variables were investigated by performing posthoc
testing by Tukey-Kramer adjustment when appropriate for multi-
ple testing.
Results
Three dogs were excluded according to exclusion cri-
teria. The ﬁnal study population consisted of 75 dogs
allocated in disease groups as follows: group A
(n = 14), group B1 (n = 27), group B2 (n = 18), and
group C (n = 16). Dog breeds in group C included 10
CKCS and 1 of each of the following breeds Cross-
breed, Springer Spaniel, Dachshund, Bull terrier, Shet-
land Sheepdog, and Yorkshire Terrier. Baseline
characteristics, conventional echocardiographic vari-
ables, cTnI, and concentrations of the diﬀerent markers
of oxidative stress of the ﬁnal study population are
shown in Table 1. All dogs in group C received cardiac
medication as follows: diuretics (n = 15), pimobendan
(n = 12), angiotensin converting enzyme inhibitor
(n = 12), digoxin (n = 3), and hydralazine (n = 2). One
Table 1. Dog characteristics, echocardiographic variables, cardiac troponin-I, and concentrations of plasma oxida-
tive stress markers in 75 dogs with no or diﬀerent severities of myxomatous mitral valve disease.
Disease group N A B1 B2 C
Total number 75 14 27 18 16
Sex (female/male)* 75 7/7 18/9 9/9 2/14
Age (years) 75 4.8 [4.2;5.9]B1,C 6.5 [6.0;7.8]A,C 7.5 [5.3;8.4]C 11.0 [9.6;12.9]A,B1,B2
BCS (3 + 4/5/6 + 7) 72 4/7/3 5/10/11 4/8/6 2/4/8
BW 74 8.3 [7.6;8.8]C 9.4 [7.9;10.5] 9.1 [8.4;10.4] 11.0 [9.9;13.1]A
Passive smoking (y/n) 75 6/8 6/21 4/14 3/13
Neutered (y/n) 75 2/12 4/23 3/15 3/13
SBP (mmHg) 61 151 [140;164] 154 [143;162] 147 [138;155] 150 [143;162]
DBP (mmHg) 61 81 [69;87] 79 [74;88] 76 [74;79] 86 [79;92]
MBP (mmHg) 61 102 [100;109] 105 [99;112] 100 [98;107] 108 [102;116]
MR severity (mini/mi/mo or se) 75 14/0/0 2/19/6 0/7/11 0/0/16
LA/Ao 75 1.3 [1.2;1.4] 1.4 [1.4;1.5] 1.6 [1.6;1.8] 2.2 [2.0;2.5]
LVIDDN 74 1.5 [1.4;1.5]
B2,C 1.6 [1.4;1.6]C 1.6 [1.5;1.8]A,C 2.1 [1.9;2.3]A,B1,B2
LVIDSN 74 1.0 [1.0;1.1] 1.0 [1.0;1.1] 1.1 [1.0;1.2] 1.2 [1.1;1.4]
FS (%) 75 26 [24;32]C 29 [23;33]C 31 [24;38] 41 [32;45]A, B1
LVPWDN 74 0.5 [0.4;0.5] 0.5 [0.4;0.5] 0.5 [0.4;0.5] 0.5 [0.4;0.5]
LVPWSN 74 0.6 [0.5;0.6] 0.6 [0.5;0.6] 0.6 [0.6;0.7] 0.6 [0.5;0.6]
IVSDN 74 0.4 [0.3;0.4] 0.4 [0.4;0.5] 0.4 [0.4;0.5] 0.4 [0.4;0.4]
IVSSN 74 0.5 [0.4;0.5]
C 0.5 [0.5;0.6]C 0.5 [0.4;0.6] 0.6 [0.6;0.6]A,B1
Plasma cTnI (lg/L) 75 0.01 [0.01;0.02]C 0.03 [0.01;0.03]C 0.03 [0.01;0.04] 0.04 [0.03;0.08]A,B1
Serum cholesterol (mmol/L) 75 5.3 [5.0;7.4] 6.4 [5.3;8.0] 6.2 [4.7;6.8]C 7.4 [6.4;8.8]B2
Plasma MDA (lmol/L) 74 1.10 [0.83;1.29] 1.05 [0.84;1.30] 0.92 [0.72;1.24] 1.04 [0.86;1.12]
Plasma OxLDL (U/L) 74 5.65 [4.92;6.45] 5.73 [5.10;6.82] 6.27 [5.50;6.55] 6.07 [5.43;7.16]
Plasma a-tocopherol (lmol/L) 75 45.36 [38.22;52.83] 58.48 [46.69;76.30] 54.92 [47.34;61.13] 59.63 [45.27;73.18]
Plasma c-tocopherol (lmol/L) 75 0.98 [0.72;1.16] 0.94 [0.69;1.03] 0.81 [0.61;0.95] 0.94 [0.74;1.32]
BCS, body condition score; BW, body weight; cTnI, cardiac troponin-I; DBP, diastolic blood pressure; FS, fractional shortening;
IVSDN, interventricular septal thickness in diastole normalized for BW; IVSSN, interventricular septal thickness in systole normalized for
BW; LA/Ao, ratio of left atrium to aortic root; LVIDDN, left ventricular end-diastolic diameter normalized for BW; LVIDSN, left ventric-
ular end-systolic diameter normalized for BW; LVPWDN, left ventricular free wall thickness in diastole normalized for BW; LVPWSN, left
ventricular free wall thickness in systole normalized for BW; MBP, mean blood pressure; MR, mitral regurgitation by jet area method
where mini=minimal, mi=mild, mo=moderate, se=severe (mini: <20%, mi:20–50%, mo or se: >50%); SBP, systolic blood pressure. Values
reported are median and interquartiles. Within each row, superscripts A,B1,B2,Crepresent the group from which there is statistically signiﬁ-
cant diﬀerence.
*Sex (P = .008) diﬀered signiﬁcantly among disease groups.
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dog did not receive diuretics at the time of examination,
but subsequently responded well to diuretic treatment
initiated on the day of examination.
The following intra-assay CV% were obtained:
MDA: 13.0%, oxLDL 9.6%, a-tocopherol: 2.5%, and
c-tocopherol: 5.6%.
Regression Analyses
Results from the univariable regression analyses are
provided in Table 2.
The ﬁnal multivariable analyses resulted in the fol-
lowing associations: Only serum cholesterol concentra-
tion (b = 0.07, adjusted R2 = 0.2, P = .0003) was
associated with plasma MDA concentration.
Plasma oxLDL was associated with sex (P = .01) and
serum cholesterol concentration (b = 0.03, P = .04).
The model had an adjusted R2 of 0.1. Females had sig-
niﬁcantly lower plasma oxLDL concentration (Fig 1).
When excluding serum cholesterol concentration from
the analysis, sex (P = .01) remained signiﬁcant and the
adjusted R2 of this model was 0.07.
Only a positive association with serum cholesterol
concentration (b = 0.15, adjusted R2 = 0.5, P < .0001)
was found for plasma a-tocopherol concentration.
When excluding serum cholesterol from the multivari-
able analysis, BCS (adjusted R2 = 0.2, P = .0004) was
signiﬁcantly associated with plasma a-tocopherol con-
centrations and dogs with BCS ≤ 4 and BCS 5 had sig-
niﬁcantly lower plasma a-tocopherol concentrations
compared to dogs with BCS ≥ 6 (Fig 2).
Regarding c-tocopherol concentration, a positive
association with serum cholesterol concentration
(b = 0.11, P < .0001) was found. Signiﬁcantly increased
plasma c-tocopherol concentrations in neutered
(P = .003) dogs also were found (Fig 3). The adjusted
R2 of the model was 0.4. When excluding serum
cholesterol concentration from the analysis, BCS
(P = .003) also was associated with plasma c-tocopherol
concentration (in addition to neuter status [P = .003]).
Dogs with BCS 5 had signiﬁcantly lower plasma c-toco-
pherol concentrations compared to dogs with BCS ≥6
(Fig 4). The model had an adjusted R2 of 0.2.
Table 2. P values of the univariable analyses in 75
dogs with no or diﬀerent severities of myxomatous
mitral valve disease.
Response Variables
MDA* OxLDL* a-tocopherol c-tocopherol
Explanatory
variables
Disease group 0.73 0.56 0.51 0.42
Sex 0.099 0.012 0.92 0.52
Age 0.88 0.53 0.20 0.52
BCS 0.068 0.31 0.00045 0.0053
Passive
smoking (y/n)
0.85 0.25 0.28 0.27
Neutered (y/n) 0.52 0.28 0.24 0.0038
cTnI 0.75 0.90 0.12 0.90
Cholesterol 0.00045 0.050 <0.0001 <0.0001
BCS, body condition score; cTnI, cardiac troponin-I; MDA=-
malondialdehyde; oxLDL=oxidized low-density lipoprotein; bold
values represent variables with P < .2 that are included in multi-
variable regression analysis.
*The statistical analysis of MDA and oxLDL included 74 dogs
as 1 dog was excluded (outlier).
Sex
Fig 1. Raw data plot of plasma oxidized low-density lipoprotein
(oxLDL) concentrations in males and females. Medians are indi-
cated with horizontal lines. Horizontal bars indicate statistically
signiﬁcant comparisons and their P values from multivariable
regression analysis. n = 74.
Fig 2. Raw data plot of plasma a-tocopherol concentrations in
the diﬀerent body condition score (BCS) groups. Medians are indi-
cated with horizontal lines. Horizontal bars indicate statistically
signiﬁcant comparisons and their P values from multivariable
regression analysis. n = 72.
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Discussion
Our study suggests that sex diﬀerences exist for
plasma oxLDL concentrations because males generally
had higher plasma oxLDL concentrations. Plasma vita-
min E (a-tocopherol and c-tocopherol) concentrations
were associated with BCS, but the association did not
remain when including serum cholesterol concentration
in the multivariable regression analysis. Additionally,
signiﬁcantly increased plasma c-tocopherol concentra-
tion was found in neutered dogs. Serum cholesterol
concentrations were positively associated with all of the
evaluated markers of oxidative stress. An association
between plasma concentrations of the selected biomark-
ers of oxidative stress and clinical stage of MMVD in
dogs was not found.
Malondialdehyde is a secondary product formed dur-
ing lipid peroxidation (ie, a reaction of oxygen with
unsaturated lipids).39 In a previous study in dogs with
MMVD, no association was found between plasma
MDA and clinical stage of MMVD.20 This ﬁnding is in
accordance with our study. In contrast, recent prelimi-
nary ﬁndings have suggested a signiﬁcant relationship
between plasma MDA concentrations and heart disease
in a cohort of control dogs and dogs with diﬀerent
stages of heart disease of various causes.g Plasma MDA
concentrations in the studies diﬀer however, because
median MDA concentrations in the previous study were
approximately 4 lM20 but approximately 1 lM in the
preliminary studyg and in our study. Breed or assay dif-
ferences might account for these diﬀerences. Interest-
ingly, the recent preliminary ﬁndings indicate higher
plasma MDA concentrations in dogs with untreated
CHF compared to dogs with CHF that were receiving
cardiac treatment.g In our study, this phenomenon
could not be investigated because all dogs with CHF
had received cardiac treatment. Furthermore, although
we found no association between plasma MDA concen-
tration and clinical stage of MMVD, a possible role for
MDA in the volume overloaded heart may exist as a
previous study found increased MDA concentrations in
the cardiac tissue of dogs with volume overload-
mediated CHF due to experimentally induced MR.19
These ﬁndings might indicate that changes in tissue
MDA concentration in MMVD do exist but may not
be reﬂected in plasma MDA concentrations. Similar
plasma MDA concentrations as found in dogs have
been reported in people40, but to the best of our knowl-
edge, circulating concentrations of MDA have not been
evaluated in human patients with MR.
Low-density lipoprotein is involved in cholesterol
transport in the body.41 Oxidation of LDL has been
described as part of the atherosclerotic process in
humans,42 and several studies have identiﬁed increased
concentrations of oxLDL in human patients with coro-
nary artery disease. Furthermore, oxLDL has been
suggested to mediate apoptosis in human coronary
smooth muscle cells.43,44 In addition, plasma oxLDL
concentration has been suggested as a useful predictor
of coronary artery disease and of mortality in human
patients.45,46 In our study, plasma concentrations of
oxLDL were signiﬁcantly higher in male dogs com-
pared with females. To the best of our knowledge,
plasma oxLDL has not been measured previously in
dogs with MMVD. However, in accordance with our
data, human male patients appear to have higher cir-
culating oxLDL concentrations compared with
women.46 Furthermore, in humans, oxLDL has been
determined to be increased in patients with MR if
complicated by atrial ﬁbrillation compared with clini-
cally healthy controls.47
Dogs may have lower plasma oxLDL concentrations
compared with humans.30,48 This might be due to
Fig 3. Raw data plot of plasma c-tocopherol concentrations and
neuter status. Medians are indicated with horizontal lines. Hori-
zontal bars indicate statistically signiﬁcant comparisons and their
P values from multivariable regression analysis. n = 75.
Fig 4. Raw data plot of plasma c-tocopherol concentrations in
the diﬀerent body condition score (BCS) groups. Red symbols
indicate dogs that are neutered. Medians are indicated with hori-
zontal lines. Horizontal bars indicate statistically signiﬁcant com-
parisons and their P values from multivariable regression analysis.
n = 72.
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species diﬀerences and is in accordance with diﬀerences
in lipid proﬁles found in humans and dogs.49,50
In our study, plasma vitamin E (a-tocopherol and
c-tocopherol) concentrations were not associated with
clinical stage of MMVD. Accordingly, preliminary ﬁnd-
ings from another recent study showed no association
between CHF of various causes and plasma vitamin E
concentrations in dogs.g Furthermore, a study in guinea
pigs with experimentally induced heart failure reported
no diﬀerence in myocardial vitamin E (a-tocopherol)
content between sham-operated controls and sham-
operated animals.18 Interestingly, vitamin E treatment
in the guinea pigs did improve hemodynamic function
(as assessed by LV function and blood pressure). The
beneﬁt of vitamin E supplementation in cardiac func-
tion also has been reported in experimentally induced
MR in dogs.19 In the previously mentioned study,
plasma vitamin E (a-tocopherol) was signiﬁcantly lower
in dogs with CHF (caused by MMVD or DCM), sug-
gesting a depletion that could be caused by increased
ROS scavenging.20 The discrepancy between vitamin E
status in the present study and the previously men-
tioned study might be a result of the higher number of
dogs included in our study, breed diﬀerences, or both.
Although the reported associations diﬀer, vitamin E
concentrations in our study and previous studies on
dogs with MMVD were similar.20,51,h Because vitamin
C is capable of regenerating vitamin E in vitro52, it
would have been interesting to know the plasma vita-
min C concentrations in the dogs to determine whether
vitamin C had been utilized to restore vitamin E con-
centration in dogs with severe disease or whether nei-
ther vitamin E nor vitamin C concentrations were
decreased, suggesting no alterations in antioxidant sta-
tus. Surprisingly, the previous study reported a signiﬁ-
cant increase in plasma vitamin C concentrations in
dogs with CHF compared with healthy controls.20
However, because dogs in contrast to humans are cap-
able of synthesizing vitamin C, this may be explained as
a compensatory response.
A recent study in humans reported increased concen-
trations of biomarkers of oxidative stress and decreased
circulating concentrations of antioxidants (including
both a-tocopherol and c-tocopherol) in candidates for
cardiac surgery (including patients undergoing mitral
valve surgery) compared with controls.53 Interestingly,
among diﬀerent etiologies of heart disease, mitral
patients had the highest levels of oxidative stress and
more prominent impairment of factors involved in nitric
oxide generation.53 Compared with humans, the plasma
concentrations of a-tocopherol appear to be higher,
whereas the concentrations of c-tocopherol seem to be
lower, in dogs.53,54
Our study indicates a tendency toward increased vita-
min E concentrations in overweight dogs. However, it is
worth noticing that no severely obese dogs participated.
Vitamin E is a fat-soluble vitamin stored in adipose tis-
sue, and previous studies in humans have shown an
association between vitamin E concentrations and circu-
lating cholesterol concentrations.54–56 When serum
cholesterol concentration was taken into account in our
study, the association with BCS disappeared. This ﬁnd-
ing is in accordance with a study in humans reporting a
positive relationship among plasma a-tocopherol, per-
centage fat mass, and age that disappeared when adjust-
ing for plasma cholesterol concentration.56 However,
results regarding the relationship between vitamin E
and overweight in humans are conﬂicting. Another
study found a positive association between body mass
index and serum vitamin E (a-tocopherol) even when
taking serum cholesterol concentrations into account.55
Vitamin E might be associated with cholesterol in dogs
in a similar manner as in humans, although lipoprotein
composition in dogs and humans diﬀers.49,50 In dogs,
high-density lipoprotein (suggested to protect against
atherosclerosis) is the most abundant plasma lipopro-
tein, whereas low-density lipoprotein (suggested to con-
tribute to atherosclerosis) dominates human plasma.49,50
Discrepancies in markers of oxidative stress between
humans and dogs may be explained by the high number
of patients with ischemic heart disease included in the
studies of humans whereas MMVD in dogs is consid-
ered to be of nonischemic origin, and both etiology and
duration of the heart disease may be of importance for
these markers.57,58 However, very few studies have
assessed circulating markers of oxidative stress in people
with MR.15,47,53
Although circulating biomarkers of oxidative stress
were not associated with MMVD in our study and
the associations reported were relatively weak, oxida-
tive stress may play a role in the pathogenesis of
MMVD. Studies in humans and animals with experi-
mentally induced and spontaneously occurring MR
and MMVD indicate the presence of oxidative stress
in the myocardium.14,18,59,60 Tissue analysis may be nec-
essary to identify these changes or circulating concentra-
tions of these speciﬁc oxidative stress markers may not
represent the myocardial oxidative stress levels and other
circulating markers of oxidative stress may have been
more informative. Previous studies in dogs have found
alterations in other circulating markers of oxidative stress
in dogs with MMVD and in humans with MR.15,20,21
Limitations of our study include diﬀerences in dietary
regimens and supplementation which may have inﬂu-
enced antioxidant concentrations and markers of oxida-
tive stress. Although the dogs were fasted for at a
minimum of 6 hours before blood sampling, daily varia-
tions (partly due to variation in dietary intake) in blood
concentration of vitamins may have inﬂuenced the
results.61
The oxLDL assay used in our study has not been for-
mally validated in dogs (this was not possible because
the assay kit is no longer commercially available) and
thus actual numbers reported should be interpreted with
caution. Breed distribution among groups diﬀered
because various breeds with CHF were included (group
C) to increase the number of dogs in this group. It
would have been preferable if all dogs with CHF had
been CKCS.
Additionally, minor deviations from reference values
in CBC and serum biochemistry results were allowed
considering the high number of geriatric dogs included
300 Reimann et al
in the study. These deviations may have inﬂuenced
results because they could be a sign of early or mild dis-
ease. Another limitation of our study is the diﬀerent
cardiac medications given to all dogs with CHF.
Because individual dogs respond diﬀerently to cardiac
treatment, it was not considered ethically justiﬁable to
standardize cardiac medications. However, several types
of cardiac medication have been suggested to have
antioxidant properties.62,g
Conclusions
Our results did not identify an association between
clinical stage of MMVD and biomarkers of oxidative
stress in dogs. However, serum cholesterol concentra-
tion was associated with all markers of oxidative stress,
and oxLDL was associated with sex. Vitamin E was
associated with neuter status and BCS. Circulating con-
centrations of MDA, oxLDL, and vitamin E may not
be optimal markers for assessing the degree of oxidative
stress in dogs with MMVD.
Footnotes
a Vet HDO monitor (Memodiagnostic), S+B medVET GmbH,
Babenhausen, Germany
b Mercodia AB, Uppsala, Sweden
c Access Systems AccuTnI Assay, Beckman Coulter Inc, Fullerton,
CA
d EchoPAC PC. Version 112, GE Vingmed Ultrasound AS, Hor-
ten, Norway
e Vividi echocardiograph, GE-medical, Milwaukee, Wisconsin
f R studio, version 0.98.1091, © 2009-2014 RStudio, Inc, Boston,
Massachusetts
g Petric AD, Verk B, Salobir J, et al. Plasma Vitamin E, Plasma
Malondialdehyde and Serum NT-ProBNP in Dogs with various
Stages of Heart Failure (abstract). J Vet Intern Med
2014;28:1008–1008
h In the study by freeman et al.51, a typographical error in the
vitamin E concentration units (a-tocopherol and c-tocopherol)
have been conﬁrmed by the author. The reported unit lg/dL
should have been lg/mL
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